Article
Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 1998
Sparreboom A, Verweij J, van der Burg M E, Loos W J, Brouwer E, Viganò L, Locatelli A, de Vos A I, Nooter K, Stoter G, Gianni L
Abstract excerpt
The purpose of the present study was to characterize the distribution and elimination kinetics of the paclitaxel vehicle Cremophor EL (CrEL), a polyoxyethylated castor oil that can modulate P-glycoprotein-mediated multidrug resistance in vitro. The pharmacokinetics of CrEL were studied using nonc...
Topics
- ATP Binding Cassette Transporter, Subfamily B, Member 1
- Adult
- Aged
- Antineoplastic Agents, Phytogenic
- Antineoplastic Combined Chemotherapy Protocols
- Body Fluid Compartments
- Cisplatin
- Clinical Trials, Phase I as Topic
- Doxorubicin
- Drug Resistance, Multiple
- Female
- Glycerol